ECCVID 2020 - High prevalence of fatigue following SARS-CoV-2 infection independent of COVID-19 severity

  • Priscilla Lynch
  • Actualités des congrès
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Research presented at the 2020 ESCMID Conference on Coronavirus Disease (ECCVID), held online from 23-25 September, shows that persistent fatigue occurs in more than half of patients recovered from COVID-19, regardless of the seriousness of their infection.

“Fatigue is a common symptom in those presenting with symptomatic COVID-19 infection. Whilst the presenting features of SARS-CoV-2 infection have been well-characterised, the medium and long-term consequences of infection remain unexplored,” explained study lead author Dr Liam Townsend, St James’s Hospital and Trinity Translational Medicine Institute, Trinity College, Dublin, Ireland.

The study used a commonly-used scale to determine fatigue in recovered patients, called the Chalder Fatigue Score (CFQ-11). They also looked at the severity of the patient’s initial infection (need for admission, and critical/intensive care), their pre-existing conditions including depression, and various markers of immune activation (white cell counts, C-reactive protein, Interluekin-6, and sCD25).

The study included 128 participants (mean age 50 years; 54% female) who were recruited consecutively at a median of 10 weeks following clinical recovery from SARS-CoV-2 infection. More than half reported persistent fatigue (52.3%; 67/128) at this point.

Of the patients assessed in this study, 71/128 (55.5%) were admitted to hospital and 57/128 (44.5%) were not admitted. “Fatigue was found to occur independent of admission to hospital, affecting both groups equally,” explained Dr Townsend.

There was no association between COVID-19 severity (need for inpatient admission, supplemental oxygen or critical care) and fatigue following COVID-19. Additionally, there was no association between routine laboratory markers of inflammation and cell turnover (white blood cell counts or ratios, lactate dehydrogenase, C-reactive protein) or pro-inflammatory molecules (IL-6 or sCD25) and fatigue post COVID-19.

Female gender and those with a pre-existing diagnosis of depression/anxiety were over-represented in those with fatigue. Although women represented just over half of the patients in the study (54%), two-thirds of those with persistent fatigue (67%) were women.